{"name":"Sen-Jam Pharmaceutical","slug":"sen-jam-pharmaceutical","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Ketotifen/Indomethacin","genericName":"Ketotifen/Indomethacin","slug":"ketotifen-indomethacin","indication":"Allergic conditions (specific indication in phase 3 not publicly detailed)","status":"phase_3"},{"name":"Treatment E- Fexofenadine HCl 120mg","genericName":"Treatment E- Fexofenadine HCl 120mg","slug":"treatment-e-fexofenadine-hcl-120mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Ketotifen/Indomethacin","genericName":"Ketotifen/Indomethacin","slug":"ketotifen-indomethacin","phase":"phase_3","mechanism":"Ketotifen is a mast cell stabilizer and H1-receptor antagonist, while indomethacin is a non-selective NSAID that inhibits cyclooxygenase, together reducing allergic inflammation and pain.","indications":["Allergic conditions (specific indication in phase 3 not publicly detailed)"],"catalyst":""},{"name":"Treatment E- Fexofenadine HCl 120mg","genericName":"Treatment E- Fexofenadine HCl 120mg","slug":"treatment-e-fexofenadine-hcl-120mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNV0hsY2pKeHlaNllaWm9xQUpjUmc2RFZlT0ZZZWNnSURUQWFsMkxoaThvSHVWRFVORW5rWllXWVo3THBOQ29LN0ZSNTllSEMzSDdJQVcyTXVCcUlNTHlyWG1ZWVpyQjlHYWhkd0E5eDdkZG9sdDRkSnZRZDYwRzR5R0VDRnBEMldSb0E?oc=5","date":"2025-12-11","type":"trial","source":"Yahoo Finance","summary":"Sen-Jam Pharmaceutical Secures Major Strategic Partnership with TASK Clinical to Fund Two-Thirds of Phase 3 Trial for SJP-001 - Yahoo Finance","headline":"Sen-Jam Pharmaceutical Secures Major Strategic Partnership with TASK Clinical to Fund Two-Thirds of Phase 3 Trial for SJ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPckc3aUR3TTRPMjVnQkFKRmxNRVZTQk5XdG41T0tZZnZnaDNERENKemd4dmNpRFhBU1dycV96MTQxVzBidkYyWTlSamVmSmhBQ3FGVGRkY0p2MndhT0Q4UXMwSThfNDBLWTJyWGd2akZZRUNHZGdFUFhoS3pqRGZ5cDFvVVQ5VmE2bHlTemIxcWM5VXhHMWc?oc=5","date":"2025-12-11","type":"pipeline","source":"seekingalpha.com","summary":"Takeda: Lack Of Realistic Upside In Japanese Pharma (NYSE:TAK) - seekingalpha.com","headline":"Takeda: Lack Of Realistic Upside In Japanese Pharma (NYSE:TAK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxNajduN2pwRXZRN2EtcUhzRHZLc0FhOVNFUHN3SkZPd1g4eXVsTlV4YnJHalYyTlRlWG1WZzBlX05OZWJjWkt4NFFndjRwbnpGNEZMUGUxY2FtTEdjb0JubWV2Sk5mdlNQa2h6enQxR3BXNnBoSUFsN1ZQUE0xTThqNl9KelpBUG41T2o3aDVIaEFHUDZkNW1MVEYwLTE3N0JLbUkxclFiSlQtWkZlUVZMdUhOc0MtX2w3Z3VNeEhmZGFLcjM2QWtrUmxkbmlHRFp3SlB2ZUFQOTVSWTJTZWR5TzN0Vi1rbHAzWV85dEFXbXNKU3lTSjl3YzFPaDhYUjFwd0VqMmNlNHJMVVEzR1JvcUlNdjhoNVV1QldMbEJjRG1FN1M2d2c?oc=5","date":"2025-10-17","type":"patent","source":"PR Newswire","summary":"Sen-Jam Pharmaceutical Advances Addiction Therapeutic Platform with Breakthrough Preclinical Results Leading to Patent for Stimulant Withdrawal - PR Newswire","headline":"Sen-Jam Pharmaceutical Advances Addiction Therapeutic Platform with Breakthrough Preclinical Results Leading to Patent f","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxPbFFyVmxCZUVZNTlhMHFXOUROdjJOLUI3SnVZZ3FxTlFQZEdMWU95ZWdpZk9SVW9mekFET0NSd2xoRmdTanZGcHA3alhIVXNVaDNWRUNiWVR5NF9mZTlPV012Qzc0d3pWb0NPTVZsYUxMUW5wTFp5OUlnWmhhQWVXSEl3TlpPWm5kY2VhM3dqeEZJbkd5dUw1czFFT1NubXFIR1NCV3RjNHZCelBKVUxSaFloVFBsQ2RKd3o3NUdTUWFXaFdTbEVxLUd5ZjZNTzBKZE1QMDV5Zm1ad3lfYTFxSDVSajFFVU5RMjI0QUlpRzZ6aEl3dnVTT3dNUlZaYTQ?oc=5","date":"2025-07-25","type":"regulatory","source":"PR Newswire","summary":"Sen-Jam Pharmaceutical Advances First-in-Class FDA Hangover Prevention Therapy, SJP-001, to Phase 2 Trials in Canada - PR Newswire","headline":"Sen-Jam Pharmaceutical Advances First-in-Class FDA Hangover Prevention Therapy, SJP-001, to Phase 2 Trials in Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQcWNPZFNLNExkbnlLQ2p3Q0dWTlFXQzBSaDJfRnhpZTZoNDgwZ0FydVMxM0ZfRTJacnNQX1c2S1NJUkRpMFdYczB1cXplbmctT2NYMFBlZnBVS1QwS1VZY1RQa2dsZEpLNHZlMHZZeTVidUFWY2RVTlM1cmpzWjlJYThjdDJvVVJOb1hvU05xSXQxZ2RsWDRfRVVrbFRydjB1NGVIejNrNE9CdnhiOFRkNFVfZ3lxOFBJWVMzVGhoclE5M0lsclpGZEc3TzI?oc=5","date":"2025-01-22","type":"trial","source":"Pharmaceutical Executive","summary":"Sen-Jam Partners Strikes Deal with 5 Horizons Capital to Support Phase II Trial of SJP-001 for Inflammation, Metabolic Health - Pharmaceutical Executive","headline":"Sen-Jam Partners Strikes Deal with 5 Horizons Capital to Support Phase II Trial of SJP-001 for Inflammation, Metabolic H","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFB5UDl5SkdiWHZFa1AzUlp0dTBNQ0tJMWpvWnZkS3R5a3BBRGRfMm1FR2NKOGkwSTBPcDVBYy03N20xd3VZQlpYVkFjM2VDSk05UnRiSnZJWDl6RjdNbDQ2TGx5QllabmliZDBuYVFteHY1UQ?oc=5","date":"2025-01-16","type":"trial","source":"Clinical Trials Arena","summary":"Sen-Jam reports positive outcomes from Phase II trial of Covid-19 therapeutic - Clinical Trials Arena","headline":"Sen-Jam reports positive outcomes from Phase II trial of Covid-19 therapeutic","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQN2txWFFTUk4xVm1tYjN2MjI4SFJldWRsUm1PdGNrTGM3NTBBU05uNk5VcW9vSnRJTmxJWG8wRy1PWFhVY3JJTjZQTml4dU9XQVZPVmhtM1piWFNvUGMtdUdkYVRmU016VzBGZ3M3R2w0UjlJdWZxVWIzTEQ2ZU1keW1aWnJGcjI1aGlTdWJEajhZZmRnUnJjSTlGRkl2ZmVoOXRyN0FqMkU1aXYxa3lHb2JlYw?oc=5","date":"2024-11-19","type":"trial","source":"Clinical Trials Arena","summary":"Sen-Jam Pharma launches Phase II trial of hangover prevention treatment - Clinical Trials Arena","headline":"Sen-Jam Pharma launches Phase II trial of hangover prevention treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOUWJlOW9XNzh5ZnFCZkJwYmZnQmdlTHhNdmcxQ1YyckV1aWVLZnc0WmhnQ3VBNGFaNG5IWGNLb1NWNkZtMkdIUWx4TzdUSjhKeVFkTllmZVR6dnA0LWtzdUYybHoxU1JXaEl0OGZ3TEV2ZVVRbm9NdG8xRVR4TmJKaFExeUQ5QjJLZlFra2N0eDM4SkdoM2R6ci1Jb19Pc1ZRX3VlM1huMEtDUkJXeW4taA?oc=5","date":"2024-04-10","type":"deal","source":"Contract Pharma","summary":"Sen-Jam Pharmaceutical Enters Strategic Partnership with KVK-Tech - Contract Pharma","headline":"Sen-Jam Pharmaceutical Enters Strategic Partnership with KVK-Tech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxQS2dDbGlUcThUb2RMUXl0NUhvbkpXUnZuNDF2eXVWN3dEUmozdGNlUktCYkE0SzYxWlpyUGYzR21QOHpDQzZKVlN2bWZvdWdjSkhySW4yNlFNcUhlRGRiRXRjRTU3MktoZ2tNMmR0NklEWGZDSDBQR3NLUC1sSVRuSE9kb09ZVUZoUlBhVkkwaWUyRmkzRFRhaWdTR1BvV0Jhc2Qzc3hCWlBYeEg2cFRoVVVpVi1FcFh0NUxmdDJqb0ZzYU9VTEtFX3gtWWRGQXBEQmc5M0tGY1hqMDBFaHJFTjJfNE5jd1FHY3NvaENYQ2FXdjM3NG1qUEp5RkVKam0xdVE?oc=5","date":"2022-06-20","type":"pipeline","source":"PR Newswire","summary":"Sen-Jam Pharmaceutical Names Award-winning Scientist and Thought Leader Dr. Alexander Wissner-Gross to Advisory Board - PR Newswire","headline":"Sen-Jam Pharmaceutical Names Award-winning Scientist and Thought Leader Dr. Alexander Wissner-Gross to Advisory Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPRmJmVnlVcTcwdXpsQXNWMGZHVWx0WlF5UmloNDhnY2lWa2xfMHV3dWx6blpBNUJUejc2dWp2RHE1Q21pUnE2VW1FOG1FSjIxLU5rOWVld3MxaEJ4eERaYWI2UkRTQ2FZcVVaYkdBcURyT1c1bDVXYm5fTXV3MTBpQmRrV0g4UlQxMjU2VVppX3daYThfNGIxZ29Ia3drYy0wUTBVYXRzc09pOERIWnhSbWM5ZV9ISnprS3R6NFEteXgwLWJtM1ZkOEJDbi1XMnV5MVpLN3pkNlpMdw?oc=5","date":"2022-05-11","type":"deal","source":"Business Wire","summary":"Alira Health Acquires RedCrow, an Equity Crowdfunding Platform for Healthcare Startups - Business Wire","headline":"Alira Health Acquires RedCrow, an Equity Crowdfunding Platform for Healthcare Startups","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNRXV0bGFDNC10VlE1RDdUbG5MT2dlX2dQcGZpeW5XekxnUGNJS2RwWlVTOTQzVXNUTWwwQURsa21sZHJCajEwRG9tS2pIQnhtSkRjN1JwZHdPR1VwX2tfanBoaXltZk03MExSYVEzcml4bDgyaW1MQTZzeHpialZkRDEtd1dnZFhZT1E?oc=5","date":"2021-09-03","type":"pipeline","source":"healthtransformer.co","summary":"These 15 Startups Are Finding New Ways to Tackle Addiction - healthtransformer.co","headline":"These 15 Startups Are Finding New Ways to Tackle Addiction","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}